Lipid Nanoparticle Delivery
Lipid Nanoparticle Delivery - Related Videos
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
0 Views •
Cited by 12 •
2015
In this study, a method for synthesizing ultra-small populations of biocompatible nanoparticles was described, as well as several in vitro methods by which to assess their cellular interactions.
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
0 Views •
Cited by 49 •
2016
Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic payload and subsequently explored for drug delivery applications.
08:51
Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry
0 Views •
Cited by 9 •
2013
A protocol for nanoparticle tracking analysis (NTA) and high-throughput flow cytometry to evaluate polymeric gene delivery nanoparticles is described. NTA is utilized to characterize the nanoparticle particle size distribution and the plasmid per particle distribution. High-throughput flow cytometry enables quantitative transfection efficacy evaluation for a library of gene delivery biomaterials.
09:41
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
0 Views •
Cited by 18 •
2021
Lipid nanoparticles are developed using a microfluidic mixing platform approach for mRNA and DNA encapsulation.
10:16
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
0 Views •
Cited by 3 •
2017
A liquid crystal nanoparticle (LCNP) nanocarrier is exploited as a vehicle for the controlled delivery of a hydrophobic cargo to the plasma membrane of living cells.
FAQs
Particle composition and surface properties act as design variables. By changing them, researchers can influence how well cargo remains stable, where it distributes, and how efficiently cells take it up. These properties also affect the ability to control tissue targeting and dose delivery. This tunability lets development teams balance delivery behavior with therapeutic effectiveness in medicine.
Endosomal escape helps cargo move beyond the compartment formed after cellular entry, making intracellular release possible. Without effective release, material may remain separated from the cellular environment where its therapeutic action is intended. In lipid nanoparticle delivery, this step therefore connects uptake with functional delivery and helps explain why cellular entry alone is not sufficient to achieve a useful medical effect.
The approach can handle several cargo classes, including messenger RNA, small interfering RNA, and drugs, while also supporting emerging gene-editing therapies. Cargo may be encapsulated within the particle or associated with it. This flexibility allows investigators to use the same general delivery concept across vaccination, gene silencing, drug treatment, and developing genetic medicine applications.
A development workflow can evaluate cargo protection, particle composition, surface properties, tissue distribution, cellular uptake, and release after entry. Researchers can adjust the tunable features of the particles while considering dose delivery and therapeutic effectiveness. This process helps connect physical design choices with medical performance, rather than judging a formulation only by whether it carries the intended molecule.
In medicine, lipid nanoparticle delivery supports nucleic acid vaccines, gene-silencing treatments, and emerging gene-editing therapies. Its relevance extends across payload types because particles can transport messenger RNA, small interfering RNA, or drugs. These applications show how one delivery strategy can address prevention, regulation of gene expression, and therapeutic intervention while researchers continue refining performance for precision medicine.
Researchers can judge performance through several linked outcomes: whether the cargo remains stable, reaches the intended distribution, enters cells, and is released after entry. They can then relate those delivery behaviors to therapeutic effectiveness. This multidimensional assessment is especially important in precision medicine, where tissue targeting and dose delivery must be considered alongside cellular uptake rather than treated as isolated endpoints.